Thrombosis News and Research RSS Feed - Thrombosis News and Research

Thrombosis is the formation or presence of a thrombus (blood clot) inside a blood vessel.
New technology removes blood clots

New technology removes blood clots

When a large blood clot was discovered attached to the end of a catheter inside the right atrial chamber of a patient's heart, doctors faced a daunting challenge. [More]
Complications from partial knee replacement is very small than total knee replacement

Complications from partial knee replacement is very small than total knee replacement

Partial knee replacement surgery is safer than total knee replacement, according to a new study published in The Lancet today (July 8). [More]
Members of JUGGLE network collaborate to improve project coordination

Members of JUGGLE network collaborate to improve project coordination

The field of life sciences is at the crossroads of biology and medicine and is a key component of the research portfolio of Johannes Gutenberg University Mainz (JGU). [More]
Devon Medical Products gets FDA marketing approval for extriCARE 3600 NPWT pump and foam kit

Devon Medical Products gets FDA marketing approval for extriCARE 3600 NPWT pump and foam kit

Global medical device designer and manufacturer Devon Medical Products today announced substantial additions to its Negative Pressure Wound Therapy (NPWT) wound care product line after receiving Food & Drug Administration 510(k) clearance to market its extriCARE 3600 NPWT pump and foam dressing kit. [More]
Cancer drug offers protection against thrombosis

Cancer drug offers protection against thrombosis

Case Western Reserve University researchers have discovered that an existing drug used to help cancer patients has the potential to protect thousands of others from the often-deadly impact of vascular clots. [More]
European Commission approves Boehringer Ingelheim's Pradaxa for prevention of DVT and PE

European Commission approves Boehringer Ingelheim's Pradaxa for prevention of DVT and PE

Boehringer Ingelheim today announces that Pradaxa (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE). [More]
FCVB 2014 to feature cutting edge research in basic cardiovascular science

FCVB 2014 to feature cutting edge research in basic cardiovascular science

Cutting edge research in basic cardiovascular science will be presented at Frontiers in CardioVascular Biology (FCVB) 2014, held 4-6 July at the Palau de Congressos de Catalunya in Barcelona, Spain. [More]
Incyte’s ruxolitinib Phase III study for polycythemia vera achieves primary endpoint

Incyte’s ruxolitinib Phase III study for polycythemia vera achieves primary endpoint

Incyte Corporation (Nasdaq: INCY) today announced results from the RESPONSE trial, the first pivotal Phase III study evaluating a JAK1/JAK2 inhibitor for the treatment of polycythemia vera (PV). [More]
P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

We already understand the many steps involved in blood clotting in great mechanistic detail. The process of blood vessels closing off in response to injury is necessary for preserving life, but blood platelets that are over-active, or activated inappropriately because of unstable plaque, can lead to heart attacks and strokes. [More]
ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST). [More]
Pivotal Therapeutics reports reduced revenue in first quarter 2014

Pivotal Therapeutics reports reduced revenue in first quarter 2014

Pivotal Therapeutics Inc., ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the three months ended March 31, 2014. [More]
Scientists report that coating stents with vitamin C reduces implants' risks

Scientists report that coating stents with vitamin C reduces implants' risks

Every year, more than 1 million people in the U.S. who have suffered heart attacks or chest pain from blocked arteries have little mesh tubes called stents inserted into their blood vessels to prop them open. [More]
FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Trimel Pharmaceuticals Corporation announced today that the United States Food and Drug Administration (FDA) has approved Natesto (testosterone), formerly CompleoTRT, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. [More]
Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

Micell Technologies, Inc. today announced that long-term clinical outcomes from its DESSOLVE I and II clinical trials were presented at the EuroPCR conference in Paris, France this week. [More]
Experts discuss potential advantages of bioresorbable vascular scaffolds at EuroPCR 2014

Experts discuss potential advantages of bioresorbable vascular scaffolds at EuroPCR 2014

At EuroPCR 2014 yesterday, experts discussed the development in evidence for bioresorbable vascular scaffolds, which represent an era of vascular restoration in interventional cardiology. [More]
Study suggests healthcare professionals must be alert to rarer, severe causes of headaches during pregnancy

Study suggests healthcare professionals must be alert to rarer, severe causes of headaches during pregnancy

Most headaches in pregnancy and the postnatal period are benign, but healthcare professionals must be alert to the rarer and more severe causes of headaches, suggests a new review published today (23 May) in The Obstetrician & Gynaecologist (TOG). [More]
Urine test can indicate presence of venous thromboembolism in patients at risks for clots

Urine test can indicate presence of venous thromboembolism in patients at risks for clots

A new study by researchers from California and Canada indicates a simple urine test can indicate the presence of venous thromboembolism, a blood clot that has broken free from its point of origin and which travels through the bloodstream, eventually lodging in a vein. [More]
FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

FDA approves Bayer's Kogenate FS antihemophilic factor VIII to prevent bleeding episodes in adults with hemophilia A

Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Bayer's Kogenate® FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A. [More]
ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD Pharmaceuticals, Inc. today reported financial results for the first quarter of 2014, including revenue from sales of Iclusig® (ponatinib) and licensing agreements. The Company also provided an update on corporate developments. [More]
Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals reports pro forma net operating loss of $22.6 million for Q1 2014

Isis Pharmaceuticals, Inc. today reported a pro forma net operating loss (NOL) of $22.6 million for the three months ended March 31, 2014 compared to pro forma operating income of $4.5 million for the same period in 2013. [More]